Last 5.23 GBp
Change Today +0.175 / 3.47%
Volume 13.2M
AVO On Other Exchanges
As of 12:30 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

advanced oncotherapy plc (AVO) Snapshot

5.10 GBp
Previous Close
5.05 GBp
Day High
5.65 GBp
Day Low
5.10 GBp
52 Week High
09/19/14 - 5.65 GBp
52 Week Low
06/4/14 - 2.45 GBp
Market Cap
Average Volume 10 Days
-0.0090 GBp
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

advanced oncotherapy plc (AVO) Related Businessweek News

No Related Businessweek News Found

advanced oncotherapy plc (AVO) Details

Advanced Oncotherapy Plc, together with its subsidiaries, provides medical technology for cancer treatment in the United Kingdom and internationally. The company offers Linac Image Guided Hadron technology, the next generation of radiotherapy with precision guided protons for the treatment of cancer; and Single Dose Intraoperative Radiotherapy technology for the treatment of early stage breast cancer. It is also involved in the development and rental of healthcare related properties. The company was formerly known as CareCapital Group plc and changed its name to Advanced Oncotherapy Plc in September 2012. Advanced Oncotherapy Plc is based in London, the United Kingdom.

13 Employees
Last Reported Date: 06/29/14

advanced oncotherapy plc (AVO) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 68.8K GBP
Executive Chairman, Member of Audit Committee...
Total Annual Compensation: 189.0K GBP
Compensation as of Fiscal Year 2013.

advanced oncotherapy plc (AVO) Key Developments

Advanced Oncotherapy plc Announces Board Appointments

Advanced Oncotherapy Plc announced that it will appoint Nicolas Serandour as Global Head of Finance and as an Executive Director, effective September 1, 2014. Graham Pughe, who will continue with the Company as Vice President of Finance and Chief Accounting Officer, will report to Nicolas. Nicolas has over fifteen years of experience in the investment banking industry, having worked at JP Morgan, Lehman Brothers and Lazard, where he was most recently responsible for coordinating the European Healthcare sector coverage.  He has extensive experience providing strategic and financial advice to senior executives and boards of directors at leading healthcare companies internationally. His transaction experience covers a wide range of private and public strategic transactions, including acquisitions, divestitures, complex alliances and funding of growth companies.

Advanced Oncotherapy Plc Announces Audited Consolidated Earnings Results for the Year Ended December 31, 2013

Advanced Oncotherapy Plc announced audited consolidated earnings results for the year ended December 31, 2013. For the year, the company reported revenue of £68,916 against £100,000 a year ago. Operating loss was £3,173,342 against £1,564,516 a year ago. Loss on ordinary activities before taxation was £3,431,146 against £1,883,733 a year ago. Loss after taxation from continuing operations was £3,431,146 or 0.86 pence per share against £1,883,733 or 1.07 pence per share a year ago. Loss attributable to equity shareholders was £3,936,291 or 0.99 pence per share against £2,713,612 or 1.55 pence per share a year ago. Cash outflows from operating activities were £2,938,305 against £1,377,226 a year ago. Purchase of plant and equipment was £543,765 against £190,983 a year ago. Capital expenditure on intangible assets was £188,349.

Advanced Oncotherapy Plc, Annual General Meeting, Jul 25, 2014

Advanced Oncotherapy Plc, Annual General Meeting, Jul 25, 2014., at 10:00 GMT Standard Time. Location: 184-192 Drummond Street.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AVO:LN 5.23 GBp +0.175

AVO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AVO.
View Industry Companies

Industry Analysis


Industry Average

Valuation AVO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 438.8x
Price/Book 5.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 736.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADVANCED ONCOTHERAPY PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at